Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

This study is comparing two treatment approaches for people with a type of advanced lung cancer (non-small cell lung cancer) that has a specific genetic change called a MET exon 14 skipping mutation. Researchers are comparing a targeted drug called crizotinib against standard chemotherapy to see which works better. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with advanced or metastatic non-small cell lung cancer confirmed by biopsy - Your tumor has the MET exon 14 skipping genetic change, confirmed by a lab - You have not received any prior treatment for your advanced-stage disease - You are in good enough physical condition to carry out daily activities (ECOG 0–1) - You have a life expectancy of at least 12 weeks - You have stable brain metastases (brain tumors that are not growing) **You may NOT be eligible if...** - You have already received chemotherapy or targeted therapy for your advanced lung cancer - You have cancer that has spread to the fluid around the spinal cord - You have had another cancer within the last 2 years - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.